Opposing Neural Effects of Naltrexone on Food Reward and Aversion: Implications for the Treatment of Obesity

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2014 Apr 26

PMID 24763910

Citations 25

Authors

Elizabeth Murray

Sietske Brouwer

Rob McCutcheon

Catherine J Harmer

Philip J Cowen

Ciara McCabe

Affiliations

Soon will be listed here.

Abstract

Rationale: Opioid antagonism reduces the consumption of palatable foods in humans but the neural substrates implicated in these effects are less well understood.

Objectives: The aim of the present study was to examine the effects of the opioid antagonist, naltrexone, on neural response to rewarding and aversive sight and taste stimuli.

Methods: We used functional magnetic resonance imaging (fMRI) to examine the neural responses to the sight and taste of pleasant (chocolate) and aversive (mouldy strawberry) stimuli in 20 healthy volunteers who received a single oral dose of naltrexone (50 mg) and placebo in a double-blind, repeated-measures cross-over, design.

Results: Relative to placebo, naltrexone decreased reward activation to chocolate in the dorsal anterior cingulate cortex and caudate, and increased aversive-related activation to unpleasant strawberry in the amygdala and anterior insula.

Conclusions: These findings suggest that modulation of key brain areas involved in reward processing, cognitive control and habit formation such as the dorsal anterior cingulate cortex (dACC) and caudate might underlie reduction in food intake with opioid antagonism. Furthermore we show for the first time that naltrexone can increase activations related to aversive food stimuli. These results support further investigation of opioid treatments in obesity.

Citing Articles

Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards.

Massaccesi C, Korb S, Gotzendorfer S, Chiappini E, Willeit M, Lundstrom J Hum Brain Mapp. 2024; 45(4):e26645.

PMID: 38445523 PMC: 10915723. DOI: 10.1002/hbm.26645.

Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging.

Campos A, Port J, Acosta A Brain Sci. 2022; 12(4).

PMID: 35447963 PMC: 9032173. DOI: 10.3390/brainsci12040431.

Brain Responses to High-Calorie Visual Food Cues in Individuals with Normal-Weight or Obesity: An Activation Likelihood Estimation Meta-Analysis.

Yang Y, Wu Q, Morys F Brain Sci. 2021; 11(12).

PMID: 34942889 PMC: 8699077. DOI: 10.3390/brainsci11121587.

Neural Correlates of Anti-appetite Medications: An fMRI Meta-analysis.

Yeung A Curr Neuropharmacol. 2021; 19(11):2049-2056.

PMID: 34521327 PMC: 9185797. DOI: 10.2174/1570159X19666210914142227.

Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.

Anker J, Nakajima M, Raatz S, Allen S, alAbsi M Drug Alcohol Depend. 2021; 225:108819.

PMID: 34182373 PMC: 8297656. DOI: 10.1016/j.drugalcdep.2021.108819.

References

Christensen R, Kristensen P, Bartels E, Bliddal H, Astrup A . Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370(9600):1706-13. DOI: 10.1016/S0140-6736(07)61721-8. View

Koppert W, Angst M, Alsheimer M, Sittl R, Albrecht S, Schuttler J . Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain. 2003; 106(1-2):91-9. DOI: 10.1016/s0304-3959(03)00294-x. View

Schienle A, Schafer A, Hermann A, Vaitl D . Binge-eating disorder: reward sensitivity and brain activation to images of food. Biol Psychiatry. 2008; 65(8):654-61. DOI: 10.1016/j.biopsych.2008.09.028. View

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

Alger S, Schwalberg M, Bigaouette J, Michalek A, Howard L . Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr. 1991; 53(4):865-71. DOI: 10.1093/ajcn/53.4.865. View

Porrino L, Lyons D, Smith H, Daunais J, Nader M . Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. J Neurosci. 2004; 24(14):3554-62. PMC: 6729741. DOI: 10.1523/JNEUROSCI.5578-03.2004. View

Dean A, Saunders J, Jones R, Young R, Connor J, Lawford B . Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. J Psychiatry Neurosci. 2006; 31(1):38-45. PMC: 1325065. View

McCabe C, Mishor Z, Cowen P, Harmer C . Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2009; 67(5):439-45. PMC: 2828549. DOI: 10.1016/j.biopsych.2009.11.001. View

Wacker J, Dillon D, Pizzagalli D . The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques. Neuroimage. 2009; 46(1):327-37. PMC: 2686061. DOI: 10.1016/j.neuroimage.2009.01.058. View

10.

Wicker B, Keysers C, Plailly J, Royet J, Gallese V, Rizzolatti G . Both of us disgusted in My insula: the common neural basis of seeing and feeling disgust. Neuron. 2003; 40(3):655-64. DOI: 10.1016/s0896-6273(03)00679-2. View

11.

Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4. View

12.

Stice E, Yokum S, Burger K, Epstein L, Small D . Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci. 2011; 31(12):4360-6. PMC: 3260083. DOI: 10.1523/JNEUROSCI.6604-10.2011. View

13.

Woolley J, Lee B, Taha S, Fields H . Nucleus accumbens opioid signaling conditions short-term flavor preferences. Neuroscience. 2007; 146(1):19-30. DOI: 10.1016/j.neuroscience.2007.01.005. View

14.

Pavlovic Z, Cooper M, Bodnar R . Opioid antagonists in the periaqueductal gray inhibit morphine and beta-endorphin analgesia elicited from the amygdala of rats. Brain Res. 1996; 741(1-2):13-26. DOI: 10.1016/s0006-8993(96)00880-3. View

15.

McCabe C, Woffindale C, Harmer C, Cowen P . Neural processing of reward and punishment in young people at increased familial risk of depression. Biol Psychiatry. 2012; 72(7):588-94. DOI: 10.1016/j.biopsych.2012.04.034. View

16.

Stice E, Yokum S, Bohon C, Marti N, Smolen A . Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4. Neuroimage. 2010; 50(4):1618-25. PMC: 3987805. DOI: 10.1016/j.neuroimage.2010.01.081. View

17.

Yeomans M, Gray R . Selective effects of naltrexone on food pleasantness and intake. Physiol Behav. 1996; 60(2):439-46. DOI: 10.1016/s0031-9384(96)80017-5. View

18.

Colasanti A, Rabiner E, Lingford-Hughes A, Nutt D . Opioids and anxiety. J Psychopharmacol. 2010; 25(11):1415-33. DOI: 10.1177/0269881110367726. View

19.

Rolls B, Rolls E, Rowe E, Sweeney K . Sensory specific satiety in man. Physiol Behav. 1981; 27(1):137-42. DOI: 10.1016/0031-9384(81)90310-3. View

20.

Lee M, Fujioka K . Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother. 2009; 10(11):1841-5. DOI: 10.1517/14656560903048959. View